Technology | June 23, 2008

1,300th TandemHeart System Procedure Completed

June 25, 2008 - Cardiologists completed the 1,300th worldwide procedure utilizing the TandemHeart System, said manufacturer CardiacAssist, marking the increased acceptance of the device and use by cardiologists and surgeons.

The TandemHeart System assists heart failure patients survive both heart attacks and high risk procedures, while providing versatility to physicians in choosing the time, place and type of treatments. The system has a high net flow rate of up to 5 lpm in the Cath Lab or up to 8 lpm in the OR as well as its flexibility and rapid deployment potential. There are a variety of FDA cleared devices that provide extracorporeal circulatory support, but all others offer less than half the net flow and hemodynamic support of the TandemHeart System.

The TandemHeart System is now used in over 100 heart centers across the U.S. Ten prestigious heart centers were recently active in helping CardiacAssist, Inc. surpass the 1,300th procedure for its TandemHeart System. These 10 heart centers include:

-- Brigham & Women's Hospital in Boston, MA

-- Cleveland Clinic in Cleveland, OH

-- Hospital of the University of Pennsylvania in Philadelphia, PA.

-- Lahey Clinic in Burlington, MA

-- Lenox Hill in New York City, NY

-- Mayo Clinic in Rochester, MN

-- Mt. Sinai in New York City, NY

-- Sacred Heart Medical Center in Spokane, WA

-- St. Luke's Hospital in Kansas City, MO

-- Texas Heart Institute in Houston, TX

The TandemHeart System is fully reimbursed by Medicare under existing DRG codes. The device can be placed rapidly in the cath lab or operating room, providing effective, reliable, temporary circulatory support for critically ill patients.

For more information: www.cardiacassist.com

Related Content

Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Overlay Init